Image: Adobe Stock SURMOUNT-OSA consisted of two phase 3 trials in which adults with obesity and moderate or severe OSA were randomly assigned to once-weekly tirzepatide or placebo for 1 year.
President John Dramani Mahama Friday swore in five more Ministers at the Flag Staff House, following parliamentary approval, bringing to 11 the total number of ministers in office so far.The five ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Salesforce has given $1 million to College Possible, the national nonprofit promoting college access by students from ...
Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
The Lobos’ home arena, aptly named The Pit, is considered one of the tougher arenas to visit in the Mountain West — last week ...
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...
The Lobos’ home arena, aptly named The Pit, is considered one of the tougher arenas to visit in the Mountain West — last week ...
On Tuesday night, Boise State basketball led Wyoming 50-21 by halftime and looked like the best-shooting team in the Mountain ...